The purpose of this study is to determine whether the addition of an investigational medication, axitinib, to radiation therapy will improve the outcome of treatment in patients, above the age of 70.
The addition of axitinib to standard treatment is experimental and has not been approved by the United States Food and Drug Administration (FDA). Axitinib works by preventing new blood vessels from forming, and tumors need to make new blood vessels in order to grow. The study will find out what effects, good or bad, axitinib has on the tumor. In addition, this study will try to determine whether the response to axitinib and the overall outcome depends on certain characteristics of your tumor.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
1
5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
University of Cincinnati
Cincinnati, Ohio, United States
Overall Survival
Time frame: average 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.